Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Issues Notification on New Format for Package Inserts
June 9, 2017
- MHLW Study Puts Global Biosimilar Market at 1-3 Trillion Yen in 2020
June 8, 2017
- Govt to Erase Reference Pricing from Honebuto Policy, though Proposal Still Alive
June 8, 2017
- Tweaking Likely for Honebuto Wording on Reference Pricing, Integration of Gx Price Bands
June 7, 2017
- Avastin’s Orphan Status Withdrawn for Pleural Mesothelioma
June 6, 2017
- MEXT to Consider Company Payment Probe for Private Univ. Hospitals: Official
June 5, 2017
- Inject Intensive Resources for Healthy Lifespan Extension: Honebuto Draft
June 5, 2017
- Draft Honebuto Policy OK’ed by CEFP, Says Distinguish “Me Too” Drugs from Pioneering Meds
June 5, 2017
- MHLW Mulling to Add Clinical Trial Data for Generic Labels
June 2, 2017
- 4 Eligibility Criteria Presented for Conditional Early Approval System
June 2, 2017
- 3rd Sakigake Invitation for Drugs Slated for This Autumn: MHLW
June 2, 2017
- Honebuto Policy to Incorporate Timeline for Drug Pricing Overhaul
June 2, 2017
- MHLW Proposes Thresholds for 5-Scale Cost-Effectiveness Ratings: Chuikyo
June 1, 2017
- Chuikyo Members Oppose Reference Pricing System for LLPs
June 1, 2017
- Payer Reps Push Earlier Application of “Z2” Price Cut for LLPs with Low Gx Rates: Chuikyo
June 1, 2017
- MHLW Advisory Panel Gives Nod to Eli Lilly’s JAK Inhibitor Baricitinib
May 31, 2017
- PhRMA Calls for Expedited Discussions on Inclusion of Vaccines in Public Vaccination Programs
May 31, 2017
- MHLW to Take Strict Action on Xarelto Side Effect Case: Minister
May 31, 2017
- MHLW Orders Label Revisions for Pneumovax NP, 3 Other Products
May 31, 2017
- Lyrica OD Tablets, Other New Dosage Forms to Join NHI Price List on May 31
May 30, 2017
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…